Pregnane X Receptor (PXR) Antagonists for Non-Alcoholic Fatty Liver Disease
孕烷 X 受体 (PXR) 拮抗剂治疗非酒精性脂肪肝
基本信息
- 批准号:8905004
- 负责人:
- 金额:$ 30万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2017-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAmericanAnimal ModelAntidiabetic DrugsApplications GrantsBiological AssayCaco-2 CellsChemicalsChemistryCholesterolCirrhosisCollaborationsCountryDataData ReportingDiabetes MellitusDiet ModificationDiseaseDisease modelDockingDrug KineticsEstrogen Receptor alphaExcretory functionExerciseFatty LiverFluorescence Resonance Energy TransferFoxesFutureGeneticGenetic TranscriptionGoalsHalf-LifeHepatitis CHepatocyteHumanIn VitroIndividualInhibitory Concentration 50LaboratoriesLeadLigand BindingLigandsLipidsLiver diseasesMedicineMetabolicMetabolic syndromeMetabolismMicrosomesMidazolamModelingMusObesityOral AdministrationPPAR gammaPathway interactionsPeer ReviewPermeabilityPersonsPharmaceutical ChemistryPharmaceutical PreparationsPharmacodynamicsPharmacologic SubstancePhasePlasma ProteinsPopulationPositioning AttributePregnenolonePreparationPrevalencePrimary carcinoma of the liver cellsPropertyProtein BindingPublicationsReceptor ActivationReflex actionScientistSiteSmall Business Innovation Research GrantSolubilityStructure-Activity RelationshipTherapeutic AgentsToxic effectVitamin EWorkabsorptionanalogaqueousbasecollegecomputational chemistrydesigndrug candidatedrug developmentdrug standardefficacy evaluationimprovedin vitro Assayin vivoin vivo Modelliver transplantationmeetingsmouse modelnon-alcoholic fatty livernonalcoholic steatohepatitisnovelpre-clinicalpregnane X receptorprogramspublic health relevancescaffoldstructural biology
项目摘要
DESCRIPTION (provided by applicant): Non-Alcoholic Fatty Liver Disease (NAFLD) is a malady of increasing prevalence because of the growing population of individuals with obesity, metabolic syndrome and diabetes. This multifactorial disorder, due to both environmental and genetic factors, affects 30% of Americans with a prevalence of nearly 90% in obese individuals. NAFLD can lead to non-alcoholic steatohepatitis (NASH) with a prevalence of 25% in persons with obesity, and NASH in turn can lead to hepatocellular carcinoma, and cirrhosis. The pregnane X receptor (PXR) has emerged as a potential target for treatment of NAFLD as activation of this receptor results in hepatic steatosis in animal models. We have identified and characterized novel human pregnane X receptor antagonist FLB-12 that specifically disrupts the function of activated (agonist ligand-bound) PXR, but does not inhibit basal levels of PXR activity. This compound has shown to be a selective PXR antagonist in a variety of in vitro and in vivo models. More specifically and importantly FLB-12 was able to statistically improve an important disease component (hepatocyte ballooning) in a murine NAFLD model. However the potency and certain drug properties of FLB-12 need to be improved in order for this compound to be considered a viable predevelopment candidate. We will realize these goals by accomplishing the following specific aims: Aim 1: Identify structure-activity relationships (SAR) for allosteric antagonism of PXR to improve potency and ADME/PK properties. The goals of this aim are to increase PXR antagonist potency and selectivity as assessed by complementary in vitro assays already established in the Mani lab. Our objective is to reduce the IC50 values in each of these assays into the sub-micromolar range. Aim 2: Evaluate ADME/PK properties for PXR antagonists meeting criteria of Aim 1. We will explore potential drug properties by obtaining in vitro absorption, distribution, metabolism and excretion (ADME) data for up to 10 compounds. One or two of the most promising compounds will be evaluated for pharmacokinetic (PK) parameters in mice (IV administration) to determine in vivo terminal half-life, volume of distribution and clearance. These goals will be accomplished by combining the pharmaceutical and medicinal chemistry expertise of the scientists at the Fox Chase Chemical Diversity Center, Inc. (www.fc-cdci.com), the PXR structural biology expertise of Collaborations in Chemistry, and the extensive expertise of the Mani Lab at the Albert Einstein College of Medicine in the preclinical aspects of PXR modulators. Once we achieve the aims of this proposal, we will be well-positioned to transition into a lead optimization and full drug development program as part of the more extensive Phase II SBIR period of study where our goals would be to find preclinical drug candidates targeting PXR that we can evaluate in detailed NAFLD models under oral administration.
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jay Edward Wrobel其他文献
Jay Edward Wrobel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jay Edward Wrobel', 18)}}的其他基金
Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens
开发 FosA 抑制剂以增强磷霉素对革兰氏阴性病原体的活性
- 批准号:
10545935 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens
开发 FosA 抑制剂以增强磷霉素对革兰氏阴性病原体的活性
- 批准号:
10684118 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
INHIBITORS OF THE PHD2 ZINC FINGER TO TREAT ANEMIA
PHD2 锌指抑制剂治疗贫血
- 批准号:
9345190 - 财政年份:2017
- 资助金额:
$ 30万 - 项目类别:
Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT
PF4 小分子拮抗剂治疗和预防 HIT
- 批准号:
10016379 - 财政年份:2014
- 资助金额:
$ 30万 - 项目类别:
Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT
PF4 小分子拮抗剂治疗和预防 HIT
- 批准号:
10179443 - 财政年份:2014
- 资助金额:
$ 30万 - 项目类别:
Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT
PF4 小分子拮抗剂治疗和预防 HIT
- 批准号:
9751604 - 财政年份:2014
- 资助金额:
$ 30万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别: